Mr. Kang Tae-suk will be also responsible of the advancement of BGM-27 and Tau NonTangles™ into the market after Phase I of the project.
Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to announce the appointment of Kang Tae-suk, Pharma Medical Doctor as Senior Vice President, Head of Regulatory Affai...
